Reverse DCF
What growth does the market imply for INDRAMEDCO?
Working backwards from the current price to find the FCF growth assumption baked in.
aggressive
11.0% implied annual FCF growth
The market is pricing in above-average growth. Achievable for a high-quality business but leaves limited margin for error — any slowdown could hurt the price.
Current Price
₹377
Historical Growth
2.6%
FCF Yield
3.12%
Price / FCF
32.0x
Plain English
To justify today's price of ₹376.55, INDRAMEDCO.NS needs to grow its free cash flow at 11.0% per year for the next 10 years. That is 8.4% faster than its historical growth rate of 2.6%. This is optimistic but not impossible for a high-quality business. The stock leaves little room for error — any slowdown could hurt the price.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Historical | 2.6% | ₹190 | -49.5% |
| Half implied | 5.5% | ₹241 | -36.1% |
| GDP rate | 10.0% | ₹347 | -7.7% |
| Implied | 11.0% | ₹377 | +0.0% |
At Historical Growth Rate
DCF horizon: 10 years. At 2.6% growth, the model values INDRAMEDCO at ₹190, below today's ₹377.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, reverse DCF, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.